



Figures and figure supplements

The signaling lipid sphingosine 1-phosphate regulates mechanical pain

Rose Z Hill et al




Figure 1. S1PR3 mediates acute mechanical pain. (A) von Frey 50% withdrawal threshold measurements for *S1pr3^{+/+}* (WT, N = 8), *S1pr3^{+/-}* (HET, N = 7) and *S1pr3^{-/-}* (KO, N = 12) mice. $p < 0.0001$ (one-way ANOVA). Tukey-Kramer post hoc comparisons for KO and HET to WT indicated on graph. (B) von Frey force-response graph for WT (N = 8) versus KO (N = 12) animals; $p_{genotype} < 0.0001$ (two-way ANOVA). Tukey HSD comparisons between genotypes are indicated for given forces. (C) % withdrawal to pinprick stimulation of hindpaw for HET versus KO animals; $p < 0.0001$ (unpaired t-test; N = 5–7 mice per group). (D) Number of attempted removal bouts in tape assay for WT (N = 2), HET (N = 2), and KO (N = 5) mice; $p = 0.172$ (one-way ANOVA). (E) Baseline radiant heat measurements for WT (N = 8), HET (N = 3), and KO (N = 5) mice; $p = 0.444$ (one-way ANOVA). (F) von Frey 50% withdrawal threshold measurements for mice pre- and post-injection of 500 μ M TY 52156 (N = 10), 10 μ M W146 (N = 6), or 1% DMSO-PBS vehicle (N = 17); $p = 0.016, 0.650$ (two-tailed paired t-test comparing vehicle- vs. drug-injected paw). (G) von Frey force-response graph for mice injected with either 1% DMSO-PBS (N = 4) or 500 μ M TY 52156 (N = 4); $p_{treatment} < 0.0001$ (two-way ANOVA). Tukey HSD comparisons were made between treatment groups and significant differences at a given force are indicated on graph. Error bars represent mean \pm SD.

DOI: <https://doi.org/10.7554/eLife.33285.002>




Figure 1—figure supplement 1. Loss of S1PR3 selectively impairs mechanonociception. Related to **Figure 1**. (A) Time to righting in seconds for P7 pups per genotype for WT and KO mice; $p=0.575$ (two-tailed unpaired t-test; $N = 7$ mice per genotype). (B) (Left) Time spent scratching in response to injection of 50 mM chloroquine or PBS vehicle (VEH) in WT and KO mice; $p=0.36, 0.98$, (unpaired t-tests; $N = 3-4$ mice per group). (Right) Time spent scratching in response to injection of 27 mM Histamine or 0.1% DMSO-PBS in WT and KO mice; $p=0.51, 0.06$ (unpaired t-tests; $N = 3-4$ mice per group). (C) Normalized paw withdrawal latencies post-injection of SKI II, TY 52156, or 0.1% DMSO-PBS vehicle into the hind paw of wild-type animals; $p=0.65$ (one-way ANOVA; $N = 5$ mice per group). Unless otherwise indicated, error bars represent mean \pm SD.

DOI: <https://doi.org/10.7554/eLife.33285.003>




Figure 2. Endogenous S1P mediates acute mechanical pain. (A) von Frey 50% withdrawal measurements for mice pre- and post-injection of 50 μM SKI II (N = 8) or 10 μM S1P (N = 7); $p=0.003, 0.604$ (two-tailed paired t-tests). (B) von Frey force-response graph for animals injected with 10 μM S1P or 0.1% MeOH-PBS; $p_{genotype} >0.05$ (two-way ANOVA; N = 8 mice per group). No Tukey HSD comparisons at any force between genotypes were significant. (C) Intradermal cheek injection of 10 μM S1P, 2 μM, 0.2 μM, and 20 μL 0.3% methanol PBS (vehicle), with quantification of number of forepaw wipes over the 5 min post-injection interval; $p<0.0001$ (one-way ANOVA; N = 3 mice per condition). Dunnett's multiple comparisons p -values are represented on graph for comparisons made between treated and vehicle groups. (D) Radiant heat normalized paw withdrawal latencies 20–30 min post injection of 15 μL 10 μM S1P, 0.2 μM S1P, or 0.3% methanol-PBS vehicle (i.d.) into the hind paw of S1PR3 WT or KO mice; $p=0.0129$ (one-way ANOVA; N = 3–10 mice per condition). Dunnett's multiple comparisons p -values are represented on graph for comparisons made between treated and vehicle groups. (E) von Frey 50% withdrawal measurements for mice pre- and post-injection of 50 μM SKI II and increasing concentrations of S1P. *Figure 2 continued on next page*

Figure 2 continued

Frey 50% withdrawal measurements for mice pre- (baseline) and post-injection of 50 μ M SKI II (N = 14) and 0 (N = 4), 10 (N = 3), 75 (N = 4), or 200 nM S1P (N = 3; one-way ANOVA; $p=0.0001$). Tukey Kramer comparisons are indicated on graph. Error bars represent mean \pm SD.

DOI: <https://doi.org/10.7554/eLife.33285.005>




Figure 3. *S1pr3* is expressed in A mechanonocceptors and C thermal nociceptors. (A) (Top) Representative co-ISH of *S1pr3* (green; left) with *Scn1a*, *Npy2r*, *Piezo2*, and *Trpv1* (magenta; center) in sectioned DRG. Right column: overlay with co-localized regions colored white (10x air objective; Figure 3 continued on next page

Figure 3 continued

scale = 100 μm). (B) Bar chart showing the % of total cells expressing the indicated marker (grey) and the % of total cells co-expressing both marker and *S1pr3* (green). See Table S1 for quantification. (C) Representative IHC images of sectioned DRG from *S1pr3^{mCherry/+}* animals stained with anti-DsRed (green, S1PR3) and anti-Peripherin (left, magenta) or anti-NF200 (right, magenta). Arrows indicate co-stained cells. Images were acquired using a 10x air objective (scale = 100 μm). (D) Whole-mount skin IHC confocal images with anti-DsRed antibody (S1PR3, green) and anti-NefH antibody (NF200, magenta) in an *S1pr3^{mCherry/+}* animal (20x water objective; scale = 50 μm). Arrows indicate co-positive free nerves (left image). Arrowheads indicate NF200- free nerves (left) or S1PR3- circumferential fibers (right image). (E) Sectioned skin IHC with anti-DsRed (S1PR3) and anti-NefH (NF200, left, top right) or anti-DsRed (S1PR3) and anti-beta-tubulin III (BTIII, bottom right) antibody (magenta) in *S1pr3^{mCherry/+}* skin (20x air objective; scale = 50 μm). Arrows indicate co-positive free nerve endings (left), S1PR3-negative lanceolate/circumferential hair follicle endings (top right, arrow = circumferential, arrowhead = lanceolate), or S1PR3-negative putative Merkel afferent (bottom right). (F) (Left) Quantification of sectioned DRG IHC experiments showing % of S1PR3+ cells that co-stained with indicated markers ($n > 250$ cells per marker). (Right) Quantification of sectioned skin IHC experiments showing % of fibers positive for indicated marker that co-stained with S1PR3 (anti-DsRed; $n = 10$ images per marker from two animals).

DOI: <https://doi.org/10.7554/eLife.33285.007>




Figure 3—figure supplement 1. S1PR3 KO animals display normal representation of somatosensory neuronal subtypes. Related to **Figure 3**. (A) ISH of sectioned adult DRG from WT and S1PR3 KO animals showing specificity of *S1pr3* probes (20x air objective, scale = 50 μ m). (B) (Image) Representative **Figure 3—figure supplement 1 continued on next page**

Figure 3—figure supplement 1 continued

ISH *Trpv1* (top) and *Trpa1* (bottom) from sectioned DRG of wild-type (left) and S1PR3 KO animals (right; 20x air objective; scale = 50 μm). (C) % of total cells expressing *Trpv1* and *Trpa1* in sectioned DRG of wild-type and S1PR3 KO animals. (D) (Left) Average diameter \pm SEM of all cells in sectioned DRG from WT and S1PR3 KO animals ($p=0.36$, two-tailed t-test; $n = 437$ and 679 cells from two animals each, respectively). (Right) Average diameter \pm SD of *Trpv1+* cells in WT and S1PR3 KO DRG ($p=0.63$, two-tailed t-test; $n = 127$ and 85 cells, respectively). (E) Representative staining with anti-S1PR3 antibody (1:2000) in sectioned adult DRG from WT and S1PR3 KO animals (10x air objective, scale = 100 μm). (F) Representative IHC images of sectioned DRG from S1PR3 KO animals stained with anti-DsRed (green) and anti-Peripherin (left, magenta) or anti-NF200 (right, magenta). Images were acquired using a 10x air objective (scale = 100 μm). (G) (Left) Quantification of total percentage of cells stained with indicated markers in sectioned DRG from *S1pr3^{mCherry/+}* and S1PR3 KO animals ($n > 250$ cells per condition). (Right) Average diameter of anti-NF200 +cells in *S1pr3^{mCherry/+}* and S1PR3 KO DRG ($p=0.15$, two-tailed t-test; $n = 256$ and 194 cells, respectively). (H) Percent responders to S1P and capsaicin in ratiometric calcium imaging of wild-type and S1PR3 KO cultured DRG and TG neurons; $p<0.0001$ (one-way ANOVA; $N = 2$ DRG and 2 TG preparations of 8 wells each). Sidak's multiple comparisons p -values are represented on graph for comparisons made between genotypes. Error bars represent mean \pm SEM. (I) (Left) No primary control showing robust staining of hair follicles in whole mount skin in contrast to specific neuronal staining shown in **Figure 3D**. (Right) No primary control showing staining around hair follicles and in epidermis in sectioned skin. Scale = 50 μm (20x water objective).

DOI: <https://doi.org/10.7554/eLife.33285.008>




Figure 4. S1P activates thermal nociceptors but not mechanonociceptors. (A) (Left) Representative image of mCherry signal in live, cultured adult DRG neurons from one *S1pr3^{mCherry/+}* animal. (Right) Quantification of % of total cells expressing *S1pr3* from DRG ISH and mCherry from dissociated DRG cultures (N = 2 animals each experiment). (B) Representative traces depicting F340/F380 signal from Fura2-AM calcium imaging showing two neurons, one which responded to 1 μ M S1P, 1 μ M Capsaicin, and high K + Ringer's (red) and one which only responded to high K+ (black). (C) (Left) Fura-2 AM calcium imaging before (left) and after (center) addition of 1 μ M S1P in *S1pr3^{mCherry/+}* cultured mouse DRG neurons. Bar indicates fluorescence ratio. Right-hand image indicates mCherry fluorescence. (Right) % of mCherry neurons that are responsive to 1 μ M S1P in ratiometric calcium imaging (n > 1000 cells from 16 imaging wells from three animals). (D) Dose-response curve of mean neuronal calcium responders to varying concentrations of S1P. Concentrations used: 1, 10, 50, 100, 200, 1000, and 10,000 nanomolar (N = 2 animals). Error bars represent mean \pm SD. Black dotted line indicates sigmoidal fit for all S1P responders from which EC₅₀ was derived. All S1P responders were also capsaicin-responsive. (E) Current-clamp trace of a single wild-type neuron firing action potentials in response to bath addition of 1 μ M S1P and 1 μ M capsaicin, with Ringer's wash in-between. Four of ten neurons responded to S1P and one of one S1P-responsive also responded to capsaicin. Bar = 2 s. (F) (Left) Fura-2 AM calcium imaging after addition of 500 nM Hm1a in *S1pr3^{mCherry/+}* P0 TG neurons, which were used instead of adult DRG neurons because they respond to Hm1a without prior PGE₂ sensitization. Right-hand image indicates mCherry fluorescence. (Right) % of Hm1a-responsive P0 TG neurons that are mCherry+ (N = 1 animal, 1230 total neurons).

DOI: <https://doi.org/10.7554/eLife.33285.009>




Figure 5. S1PR3 modulates KCNQ2/3 channels to regulate AM excitability. All experiments were performed in *S1pr3^{mCherry/+}* or *-/-* DRG neurons. (A) (Left) Example traces of a single mCherry+ neuron in whole cell current clamp before and after S1P application. (Right) % change in rheobase after S1P application for *S1pr3^{mCherry/+}* (left, $n = 7$) and KO (right, $n = 12$) neurons ($p_{WT,KO} = 0.012, 0.287$; two-tailed paired t-tests). (B) % Δ in input resistance after S1P or vehicle application ($p = 0.017$; two-tailed paired t-test; $n = 4$ cells per group). (C) The S1P-sensitive current is carried by potassium. The current-voltage relationship was determined by subtraction of the post-S1P current from the pre-S1P current and reverses at -60.125 mV; $n = 6$ cells. Data were fitted with a Boltzmann equation. Pre- and post-S1P currents were measured at the indicated voltage (-100 mV to $+80$ mV, 20 mV increments) following a $+100$ mV step (100 ms). Current was quantified using the peak absolute value of the slowly-deactivating current 0–10 ms after stepping to indicated voltage. Unless indicated otherwise, all error bars represent mean \pm SEM. (D) (Graphic, top) Averaged current traces of a single mCherry+ neuron in whole cell voltage clamp recording comparing tail currents (ΔI_{tail}) pre- and post-S1P using indicated voltage step protocol. (graphic, bottom) Averaged current traces of a single mCherry+ neuron in whole cell voltage clamp recording with XE991 treatment. Holding phase (-40 mV, 150 ms) was truncated in traces. (Left graph) % Δ in outward tail current (average \pm SD after indicated treatments (1 μ M S1P, 3 μ M XE 991, or both) for *S1pr3^{mCherry/+}* medium-diameter neurons; ($p = 0.58$; one-way ANOVA; $n = 6, 8, 14$ cells) using protocol depicted at right. (Right graph) % Δ in inward tail current after indicated treatments (LINO = 100 μ M linopirdine) for *S1pr3^{mCherry/+}* medium-diameter neurons; ($p = 0.47$; two-tailed paired t-test; $n = 12$ cells).

DOI: <https://doi.org/10.7554/eLife.33285.010>




Figure 5—figure supplement 1. S1P selectively modulates potassium tail currents to increase DRG neuron excitability. Related to **Figure 5**. (A) (Left) Example trace of a single mCherry+ neuron in S1P before and after current injection. (Right) Resting membrane potential (RMP) in millivolts before and after S1P application. (B) Rheobase (nA) before and after S1P application in WT and KO neurons. (C) Current-voltage relationship for Na⁺ current before and after S1P application. (D) Current-voltage relationship for Steady-state K⁺ current before and after S1P application. (E) Percentage change in current (% Δ current) for Na⁺ and S.S. K⁺ currents in response to S1P or vehicle (VEH). (F) Percentage change in tail current (% Δ tail current) for WT and KO neurons in response to S1P or vehicle (VEH). (G) Dose-response curve for the percentage change in tail current (% Δ tail current) versus S1P concentration [S1P] nM. *Figure 5—figure supplement 1 continued on next page*

Figure 5—figure supplement 1 continued

after addition of S1P ($p=0.23$; two-tailed paired t-test; $n = 6$ cells). (B) Rheobase pre- and post-S1P application in DRG neurons; $p_{WT} = 0.011$; $p_{KO} = 0.28$ (two-tailed paired t-test). Same data are represented in **Figure 5A**. (C) Sodium I-V relationship for a representative $S1pr3^{mCherry/+}$ medium-diameter neuron pre- and 5 min post- $1 \mu\text{M}$ S1P using voltage step from -100 to $+80$ mV (150 ms steps, -80 mV holding). (D) Steady-state I-V relationship for same neuron. (E) (Left) % Δ in peak sodium current (Na^+) after S1P or 1% DMSO vehicle application for medium-diameter mCherry+ neurons; $p=0.39$ (two-tailed paired t-test; $n = 7$ cells per group). (Right) % Δ in peak steady-state current (S.S. K^+) after S1P or 1% DMSO vehicle application for medium-diameter mCherry+ neurons; $p=0.948$ (two-tailed paired t-test; $n = 7$ cells per group). (F) % Δ in inward tail current (ΔI_{tail}) after S1P or 1% DMSO vehicle application for $S1pr3^{mCherry/+}$ and KO medium-diameter neurons using a pre-pulse stimulation of $+80$ mV followed by a step to -80 mV, where (ΔI_{tail}) was calculated by subtracting the steady-state current from the absolute peak of the slowly-deactivating current at -80 mV ($p=0.014$; one-way ANOVA; $n = 10, 13, 10$ cells). Tukey Kramer post hoc p -values indicated on graph. (G) Dose-response relationship between % Δ in tail current and S1P concentration for 1 nM, 50 nM, 100 nM, and $1 \mu\text{M}$ S1P ($n = 7$ cells). EC_{50} (48.8 nM), marked by thin dotted lines, was estimated from sigmoidal fit (thick dotted line).

DOI: <https://doi.org/10.7554/eLife.33285.011>




Figure 6. S1PR3 is required for nociceptive responses of high-threshold AM nociceptors. (A) (Left) Representative traces of AM fiber activity over time in ex vivo skin-saphenous nerve recording in response to stimulation (128 mN, top) from HET (middle) and KO (bottom) mice. (Right) Mean firing rate of

Figure 6 continued on next page

Figure 6 continued

AM fibers in response to force controlled stimulation (4, 8, 16, 32, 64, 128, 256 mN). ** $p=0.001$, *** $p=0.0002$ (two-way ANOVA, Sidak's post-hoc); lines, linear regression (HET: slope = 50 Hz/N, $R^2 = 0.99$; KO: slope = 35 Hz/N, $R^2 = 0.95$). (B) von Frey threshold of AM fibers in S1PR3 HET and KO specimens. *** $p<0.0001$ (Mann-Whitney test); lines, median; boxes, 25–75 percentile; whiskers, min-max. (C) Cumulative response plot of AM fibers to force controlled stimulation (solid lines); four-parameter logistic fit from which half-maximal force was estimated for each genotype (dotted lines). (D) Conduction velocity (CV) of AM fibers in S1PR3 HET and KO mice. $p=0.65$ (two-tailed t-test); $n = 40, 36$ fibers; errors, mean \pm SEM. (E) Representative traces and binned instantaneous firing frequencies (IFF; 200 ms bins) of Non-Adapting and Adapting AMs in response to force controlled stimulation (256 mN, top) for S1PR3 HET and KO mice; blue regions, dynamic phase of stimulation (200 ms). (F). Proportion of fibers classified by pattern of mechanically evoked responses to 256-mN stimuli: Non-Responder (HET, 2/40 fibers; KO 5/36), Non-Adapting AM (HET, 18/40; KO, 29/36), Adapting AM (HET, 20/40; KO, 2/36). Non-Responders fired action potentials to large magnitude von Frey monofilaments (<0.5 mm tip diameter), but not controlled mechanical stimulation (256 mN, 2 mm tip diameter). *** $p<0.00001$ (Chi-square test).

DOI: <https://doi.org/10.7554/eLife.33285.013>




Figure 6—figure supplement 1. S1PR3 HET AM nociceptors display normal nociceptive responses. Related to **Figure 6**. (A) Mean firing rate of AM fibers in response to force controlled stimulation (4, 8, 16, 32, 64, 128, 256 mN) from **Figure 6A**, with additional data from one wild-type animal **Figure 6—figure supplement 1 continued on next page**

Figure 6—figure supplement 1 continued

($n_{WT} = 4$ fibers) (WT: slope, 57 Hz/N, R (Vriens et al., 2011), 0.98; $p=0.90$, two-way ANOVA comparing HET and WT). (B) (Left) Conduction velocities from teased fibers from 6 S1PR3 KO animals (purple, A β , centroid = 13.1 m/s; yellow, A δ , centroid = 5.7 m/s; orange, C, centroid = 0.4 m/s; $R^2 = 0.69$, N = 65 fibers). (Right) Conduction velocities from teased fibers from 1 S1PR3 HET and 6 C57BL/6 WT animals (purple, A β , centroid = 14.5 m/s; yellow, A δ , centroid = 6.8 m/s; orange, C, centroid = 0.3 m/s; $R^2 = 0.82$, N = 76 fibers). Three-term Gaussian model. X-axis plotted on a log 1.2 scale. (C) Mean firing rates during dynamic (ramp) and static (hold) stimulation for S1PR3 HET and S1PR3 KO recordings (left, Adapting AMs; right, Non-Adapting AMs; see **Figure 6E–F** for experimental details). No significant differences were found between genotypes ($p=0.227$, 0.490 (two-way ANOVA); bars, means). As shown in **Figure 6F**, the proportion of Adapting AMs was significantly lower in S1PR3 KO recordings compared with littermate controls.

DOI: <https://doi.org/10.7554/eLife.33285.014>




Figure 7. S1PR3 is dispensable for development of chronic mechanical hypersensitivity. (A) Thermal latency before and after CFA treatment (indicated by dotted line); $p_{genotype} = 0.0053$ (two-way ANOVA; $N = 5$ mice per genotype). Sidak's multiple comparison between genotypes for specific time points indicated on graph. Error bars represent mean \pm SD. (B) (Left) Normalized 50% withdrawal threshold before and after CFA treatment (indicated by dotted line); $p_{genotype} < 0.001$ (two-way ANOVA). (Right) 50% withdrawal thresholds for same experiment ($p_{genotype} = 0.1634$; two-way ANOVA). (C) (Left) Thermal latency assessed before ('Baseline') and 24 hr post CFA injection with either vehicle (CFA + VEH) or TY 52156 (CFA + TY) acutely administered; $p < 0.0001$ (one-way ANOVA $N = 5$ mice per treatment). (Right) Thermal latency assessed before and after CFA injection with either vehicle (CFA + VEH) or SKI II (CFA + SKI II) acutely administered on Day 1; $p < 0.0001$ (one-way ANOVA; $N = 5-7$ mice per treatment). Dunnett's test comparisons to baseline are indicated on graph. Error bars represent mean \pm SD. (D) (Left) 50% withdrawal threshold assessed before and 24 hr post CFA injection with either vehicle (CFA + VEH) or TY 52156 (CFA + TY) acutely administered on Day 1; $p < 0.0001$ (one-way ANOVA; $N = 5$ mice per treatment). Dunnett's test comparisons to baseline are indicated on graph. (Right) 50% withdrawal threshold assessed before and 24 hr post CFA injection with either vehicle (CFA + VEH) or SKI II (CFA + SKI II) acutely administered; p -values indicated on graph (two-tailed unpaired t-test; $N = 5$ mice per group).

DOI: <https://doi.org/10.7554/eLife.33285.016>




Figure 7—figure supplement 1. S1PR3 KO animals display normal CFA-evoked immune cell recruitment. Related to **Figure 7**. (A) Recruitment of neutrophils (Neut.) or inflammatory monocytes (IMs) to hindpaw skin 24 hr post-CFA administration in S1PR3 HET and KO mice, as a dot plot of CD11b + cells plotting Ly6G fluorescence intensity vs. Ly6C intensity (AFU). Boxes are for illustrative purposes. (B) Recruitment of immune cells, including neutrophils (Neut.) and inflammatory monocytes (IMs) to hindpaw skin 24 hr post-CFA administration in HET and KO mice, displayed as total number of cells; N = 8 mice per genotype. Sidak's multiple comparisons were made between HET and KO for each cell type.

DOI: <https://doi.org/10.7554/eLife.33285.017>




Figure 8. Proposed model illustrating a key role for S1PR3 in regulating mechanical pain in AM nociceptors. (Top) S1P promotes activation of S1PR3, which leads to inhibition of KCNQ2/3 currents and promotes normal mechanical pain sensitivity. (Bottom) Diminished S1P or S1PR3 antagonism alleviates inhibition of KCNQ2/3, leading to mechanical pain hyposensitivity.

DOI: <https://doi.org/10.7554/eLife.33285.019>